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Introduction:We have used respiratory-correlated cone beam com-
puted tomography (rcCBCT) imaging to study the volumetric and
positional changes that occur throughout the course of radical
radiotherapy in non-small cell lung cancer (NSCLC).
Methods: Tumor volumes and centers of mass were recorded and
analyzed on weekly serial rcCBCT images of NSCLC patients
treated with radical radiotherapy to a dose 45 Gy with concurrent
chemotherapy.
Results: Sixty patients with locally advanced NSCLC were in-
cluded; in 31 patients, the primary tumor was peripheral and thus
suitable for contouring. There was a mean percent decrease of
40.2% by fraction 15 and 51.1% by treatment completion. Among
all 60 patients, 19 patients (32%) had more than 30% regression by
fraction 15 and 25 patients (81%) by treatment completion. Statis-
tically significant tumor migration in at least one direction between
the first and the last 2 weeks was demonstrated in 14 of 27 patients.
Clinically relevant changes (atelectasis and effusions) were noted in
11 of 29 visually assessed patients.
Conclusions: Current rcCBCT image quality allows assessment of
tumors located more peripherally. Significant tumor regression was
documented in the majority of patients. In view of these observa-
tions, the suitability of adaptive radiotherapy in radical lung cancer
treatment should be further investigated.
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Lung cancer continues to be the most common fatal cancerin both men and women in North America, accounting for
31% and 26% of all cancer deaths, respectively.1,2 It causes
more deaths than breast, prostate, and colon cancer com-
bined. Locally advanced non-small cell lung cancer (NSCLC)
has reported 5-year survival rates in the order of 10 to 30%.3
Radiotherapy (RT) is a mainstay of the treatment of
locally advanced lung cancer, often in conjunction with
chemotherapy.2 Dose escalation and altered fractionation
have been shown to be an effective means of increasing local
control but have often resulted in higher rates of normal tissue
complications.4 Unfortunately, the large disease volume and
low tolerance of surrounding critical structures to RT limit
the potential for dose escalation.
Adaptive RT, whereby treatment plans are modified
over the course of treatment to account for individual patient
and tumor changes, is an emerging concept to improve local
control while minimizing toxicity. The widespread introduc-
tion of cone beam CT (CBCT) has enabled image-guided RT to
assess patient position for each treatment. CBCT also offers the
advantage of reduced doses to patients5 in comparison with other
image-guided RT modalities, such as Tomotherapy™ and portal
imaging, and excellent geometric precision and accuracy6,7 for
many tumors, including NSCLC.8 Respiratory-correlated CBCT
(rcCBCT) has been introduced to visualize breathing motion and
correct motion artifacts in a manner analogous to four-dimen-
sional computed tomography (4DCT).9 By allowing more accu-
rate visualization of tumors on the RT unit, CBCT and rcCBCT
may ultimately enable adaptive RT.
Based on previous studies and clinical observations, it
has been demonstrated that, in general, the majority of pa-
tients experience some tumor regression over the course of
therapy. However, it is still unclear whether the timing and
degree of regression is sufficient to allow replanning and treat-
ment adaptation. In this study, we seek to analyze serial rcCBCT
studies of NSCLC patients to monitor the magnitude of change
in tumor size, shape, and location on a weekly basis during the
course of RT in a homogenous group of locally advanced
NSCLC patients treated with concurrent chemotherapy.
PATIENTS AND METHODS
Patients
A Research Ethics Board-approved retrospective anal-
ysis of clinical data was undertaken. Consecutive patients
*Department of Radiation Oncology, University of Toronto, and Radia-
tion Medicine Program, Princess Margaret Hospital/University Health
Network, Toronto, Ontario; and †Department of Biomedical Statis-
tics, Princess Margaret Hospital, Toronto, Ontario, Canada.
Disclosure: This study received funding in part from the Fellowship pro-
gram, Department of Radiation Oncology, Princess Margaret Hospital,
the Addie MacNaughton Chair in Thoracic Radiation Oncology, Princess
Margaret Hospital, and a grant from Elekta Synergy Inc.
Address for correspondence: Jean-Pierre Bissonnette, Department of Radiation
Oncology, Princess Margaret Hospital, 610 University Ave., Toronto, ON,
Canada M5G 2M9. E-mail: jean-pierre.bissonnette@rmp.uhn.on.ca
Presented in part at the 2008 Annual meeting of the American Society of
Therapeutic Radiation Oncology, Boston, MA.
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0603-0531
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 531
with pathologically confirmed NSCLC who received radical
RT to a dose of 45 Gy or higher over at least 5 weeks with
concurrent chemotherapy (to account for the effect of che-
motherapy on tumor volumes), treated at Princess Margaret
Hospital, Toronto, Canada, between January 2006 and June
2007, were included. All patients had CBCT performed for
image localization and verification on a daily basis during
their course of radical RT as per departmental protocol.8,10
Image Acquisition and Technical Procedure
Patients were treated on a linear accelerator (Synergy,
Elekta Oncology Systems, Stockholm, Sweden), with an
orthogonally mounted kV source and amorphous silicon flat
panel detector providing a volumetric CBCT dataset repre-
senting the position of the patient before treatment. Each
CBCT dataset was acquired over 2 minutes with a full gantry
rotation of 360°, a frame rate of 5.5 Hz, and reconstructed
with approximately 660 projections. The imaging technique
was 120 kV and 0.4 mA, with a nominal dose of 6 mGy,
reconstructed at 400  400  256 voxels with a 1-mm
isotropic voxel size. For all patients, a CBCT image set was
acquired for clinical purpose after initial positioning at the
treatment unit; the CBCT was then reconstructed off-line
using the position of the diaphragm into 10 datasets, produc-
ing an rcCBCT. This was then registered to the planning
4DCT, used as a reference dataset, through the XVI software.
Image registration was done to identify and correct position-
ing errors exceeding 3 mm in any direction, using auto-
matic bone matching.8 A tolerance of 5° was allowed, as per
departmental protocol, for rotational errors; whenever this
tolerance was exceeded, the patient was repositioned and
another CBCT scan acquired. Cone beam images for frac-
tions 1, 5, 10, 15, 20, 25, and 30 (if delivered) were collected
off-line for this study. These images were first digitally
optimized and then reconstructed in four dimension to gen-
erate rcCBCT images.9 The rcCBCT data representing the
full exhale phase of respiration was generated. Therefore,
registering matching 4DCT and rcCBCT datasets that both
correspond to the full exhale phase allowed a direct compar-
ison of volumetric and positional tumor changes. After that,
the images were exported to a Pinnacle workstation (ADAC
Pinnacle3, Philips, Madison, WI) for contouring.
Contouring
The serial CBCT images were used to identify and
contour the primary gross tumor volume (GTV) in the exhale
phase of respiration on successive weeks after the start of RT.
Contours were performed in a blinded fashion with respect to
chronology during treatment. For patients with tumors that
could not be contoured, a subjective visual assessment scale
was used as described below. Contours were done at baseline
and then on rcCBCT at fractions 5, 10, 15, 20, 25, and 30.
Only the primary tumor was contoured, as it was not possible
to reliably distinguish nodal disease from normal structures.
Contours were generally performed by a single observer, but
on occasion where further verification was required, the
images were reviewed by a panel of radiation oncologists
experienced in lung cancer RT to achieve consensus. Win-
dow settings were chosen to provide the most well-defined
tumor edges, and the same window setting was used for
contouring all images for a singular patient. Patient-specific
window and level settings were necessary, as CBCT images
are affected by patient scatter; these settings were employed
throughout all images for a specific patient to facilitate
comparison of volumes.
Interfraction Tumor Migration Assessment
For each patient, tumor migration throughout a course
of RT was assessed by recording and comparing the coordi-
nates of the centroid of the tumor contoured on all serial
rcCBCT. The anterior-posterior, left-right, and superior-infe-
rior coordinates of the center of mass of each contoured
tumor were compared, after image registration based on the
spine, with the corresponding coordinates of the tumor con-
toured on the planning 4DCT. Positional changes were first
studied by comparing the average position of the tumor center
of mass of the first 2 weeks (CBCTs from fractions 1, 5, and
10) with the average center of mass position of the last 2
weeks (CBCTs from fractions 15, 20, and 25 for the 5-week
course of RT or 20, 25, and 30 for the 6 weeks patients). As
4 patients did not have baseline 4DCT data, 27 patients were
available for this analysis. A significant shift in position was
defined as a change in position beyond 2SD for each patient
rather than a specific cutoff point. Time trends were analyzed
for individual coordinates and as a vector sum.
Visual Assessment
For patients with primary tumor images not of suffi-
cient quality for contouring, a visual assessment scale was
used. Tumors were subjectively graded at fraction 15 and 30
for no volume regression, volume regression more than 10%,
or volume regression more than 30% compared with the day
1 cone beam image. This subjective grading was performed
by a single observer.
These numbers were chosen based on clinical experi-
ence and felt to represent a significant change for the pur-
poses of replanning. In addition, a study by Woodford et al.11
showed adaptive planning to be of benefit in patients whose
GTV decreased by more than 30% within the first 20 frac-
tions of treatment.
Statistical Analysis
Descriptive statistics were used to summarize changes
in the tumor volume and position. Absolute tumor volumes as
well as percentage change from the initial volume were
recorded. To account for repeated measurements per patient,
a random coefficients model was used to regress tumor
volume over time. The initial volume, dichotomized at the
median value (i.e., above or below the median), was included
in the volume regression to detect differences in volume
changes between large and small tumors. Statistical analyses
were performed using SAS version 9.1 (SAS Institute, Cary,
NC) and R version 2.7.1 (www.r-project.org). All statistical
tests were two sided, and p values less than 0.05 were
considered statistically significant.
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RESULTS
Patient Characteristics
Sixty patients were evaluated for primary lung tumor
regression (Table 1). All patients received concurrent chemo-
therapy (cisplatinum and etoposide) and were treated with
radical intent. RT was preoperative in 33 patients (45 Gy
preoperative dose in 25 fractions); 27 patients treated radi-
cally received doses of 60 to 66 Gy, all in 2 Gy per fraction
except for one patient who was treated with 65 Gy in 25
fractions.
Thirty-one patients had primary tumors surrounded by
aerated lung that provided sufficient contrast for contouring
on rcCBCT images, whereas 29 patients were assessed sub-
jectively using the visual scale described above. The group of
visually assessed patients had primary tumors in close asso-
ciation with the mediastinum.
Volumetric Changes (n  31)
For each patient, between five (n  11; prescription
dose  45 Gy) and seven (n  20; prescription dose  60
Gy) rcCBCT datasets were contoured over a course of treat-
ment. Images were contoured at datasets corresponding ap-
proximately to fractions 1, 5, 10, 15, 20, 25, and 30.
For all 31 contoured patients, the median initial tumor
volume, as assessed by day 1 cone beam images, was 63.9 ml
(range, 3.4–421.8 ml). This decreased to a median of 38.2 ml
(mean percent decrease of 40.2%; range, 1.9–184.1 ml) by
fraction 15 and further decreased to 31.2 ml (mean percent
decrease of 51.1%; range, 2.8–99 ml) by treatment comple-
tion (Figures 1 and 2). The regression in volume was not
consistent week to week. There were some increases in tumor
volume in certain weeks, and this may have been due to
contouring variability or perhaps inflammation and edema
within the tumor. Overall, the random coefficients regression
of absolute tumor volume over time detected a volume
change of 1.65 ml/fraction (95% confidence interval:
2.49, 0.82), and this change was statistically significant
(p  0.0001). The random coefficients regression of relative
tumor volume over time detected a volume change of
1.46%/fraction (95% confidence interval: 1.73, 1.19),
and this change was statistically significant (p  0.0001).
Nineteen of the contoured patients (61%) met the suggested
criterion of a decrease in GTV by more than 30% being
required to have a benefit from adaptive planning11 at fraction
FIGURE 1. Absolute volume regression of tumor
(n  31 patients) and line of mean decrease (black).
TABLE 1. Patient Characteristics
No. of Patients
Total Contoured
Total 60 31
Male/female 36/23 21/10
T stage
T1 9 5
T2 20 13
T3 17 8
T4 11 4
Tx 3 1
N stage
N0 14 6
N1 3 0
N2 28 17
N3 12 6
Nx 3 2
Dose
4500 cGy 33 18
6000 cGy 27 13
Histology
Adenocarcinoma 22 11
Squamous 11 3
Large cell 6 4
Bronchoalveolar 1 0
Carcinoma not otherwise specified 20 13
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15 (Figure 3); this increased to 25 patients (81%) by treat-
ment completion (Figure 4).
The effect of initial tumor volume on tumor regression
was also analyzed. Larger tumors had greater rates of regres-
sion (1.67%/fraction) than smaller tumors (1.24%/d)
(p  0.10).
There was variability in the rates of regression
among the 31 patients. Greater rates of tumor regression by
volume were seen during the initial weeks compared with
the latter part of treatment. We observed no statistically
significant difference between patients receiving 45 Gy
(n  11; 52% shrinkage) and those receiving 60 Gy (n 
20; 53% shrinkage).
Positional Changes (n  27)
In the group of 31 patients who were contoured, there
were 27 patients who had data suitable for evaluating posi-
tional changes. Four patients had significant shifts in the x
coordinate, four patients had significant shifts in the y coor-
dinate, and seven patients had significant shifts in the z
coordinate. Using the sum of vectors, six patients had signif-
icant displacements of their tumor center of mass. Overall, it
was found that 14 patients had significant shifts in at least one
or more coordinates between the first 2 weeks and the last 2
weeks of RT. In those patients with statistically significant
shifts in contoured tumor centroid, we did not observe any
directional trends in the shifts of the tumors.
Visually Assessed Patients (n  29)
Among the 29 visually assessed patients, there were 2
patients who were not able to be evaluated due to develop-
ment of significant atelectasis during treatment. The other 27
patients were all evaluable. Among them, nine patients had
clinically relevant findings including atelectasis formation
during treatment (five patients), atelectasis improvement (two
patients), and pleural effusion formation (two patients).
At fraction 15, of the 27 visually assessed patients, 9
were felt to have stable disease, 10 were scored as regression
between 10 to 30%, and 8 as more than 30% tumor regres-
sion. At treatment completion, of the 27 assessable patients,
8 continued to have stable disease, 5 had tumor regression
between 10 and 30%, and 14 patients had more than 30%
tumor regression. There were no patients who had evidence
of disease progression.
DISCUSSION
Summary of Findings
In our study of NSCLC patients treated radically with
concurrent chemoradiotherapy, we demonstrated that all pri-
mary tumors regress over the course of treatment with sig-
nificant regression detected in half of the patients. Combining
all patients on this study (contoured and visually assessed
patients), more than 30% tumor regression was documented
in 40% of patients mid treatment and 67% by treatment
completion. There was a trend toward greater regression rates
by volume earlier in the course of treatment, and larger
tumors achieved proportionately greater tumor regression in
the 31 contoured patients.
Significant positional changes over the course of treat-
ment were found in several patients. Overall, 52% of evalu-
ated patients had a significant shift in at least one direction
between the beginning and end of RT. While set up variabil-
ity and breathing motion were accounted for by fusing images
in the planning scan with rcCBCT images at exhale phase,
asymmetric tumor regression may result in changes in the
tumor center of mass despite the overall position of the tumor
remaining relatively stable.
These findings of significant tumor regression and mi-
gration over a course of radical RT suggest the possible
FIGURE 2. Percent regression of tumor.
FIGURE 3. Tumor regression by volume at fraction 15 for
contoured patients (n  31).
FIGURE 4. Tumor regression by volume at treatment com-
pletion for contoured patients (n  31).
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benefit of adapting radiation treatment through replanning.
Conforming to changing target volume better allows treat-
ment to be delivered to the target area and may allow
increased doses to be administered while minimizing toxicity
to surrounding critical structures. Changes in the electronic
equilibrium environment caused by shrinking tumors can also
potentially be addressed. Potential applications include large
tumors where lung toxicity is a significant concern and
tumors in close proximity to critical organs such as the spine
or brachial plexus.
Furthermore, a number of patients had clinically sig-
nificant findings of pleural effusion formation or atelectasis.
Although the eventual management in these patients was not
altered, CBCT was essential at detecting and monitoring such
changes for any deterioration, which would have necessitated
intervention.
Findings in the Literature
While it is expected that the majority of lung tumors
will regress over the course of treatment, the frequency and
pattern of tumor regression has not been well described. The
studies that have documented tumor regression over the
course of treatment12–16 had methodological limitations in-
cluding inferior imaging techniques, small sample sizes, and
heterogeneity in treatment intent and dose. The use of che-
motherapy, whether concurrent or sequential, which can in-
fluence the amount of tumor regression, is also not addressed
in most studies. Confounding factors such as respiratory
motion have also not always been accounted for, which can
affect precise determination of tumor volume and position.
Our study addresses those limitations by analyzing a larger
patient sample, with all patients treated in a standard manner,
with concurrent chemoradiation and standard fractionation
schedule, and taking into account respiratory motion. The
exhale phase of respiration was chosen in our study as it has
been shown to represent the most accurate position of the
tumor, as lung tumors spend more time in the exhale phase of
respiration than the inhale phase.17 We have analyzed weekly
CBCT images, as an earlier determination of shrinkage pro-
vides more opportunity for normal tissue sparing from adap-
tive planning. In contrast, Fox et al. used repeat CT scans
twice during the course of RT and also accounted for respi-
ratory motion. In their study of 22 patients, there was a
median GTV reduction of 24.7% and 44.3% at 30 and 50 Gy,
respectively.18
In contrast to the majority of studies, which show
considerable regression among most patients, a study by
Siker et al.19 found that 68% of their patients had stable
disease throughout the treatment. In this study, however,
several patients were treated with stereotactic radioablation
while a few others were treated with palliative doses. None of
the patients in these two groups showed any meaningful
regression.
Simulated adaptive planning has also been investigated,
and a study reported by Woodford et al.11 concluded that
adaptive planning is of benefit in those whose GTV decreased
by more than 30% within the first 20 fractions of treatment.
In contrast, another study by Gillham et al. found only modest
benefit with adapting RT over the course of RT in the context
of dose escalation. However, patients in this study were not
treated with concurrent chemotherapy and may not have had
as much regression during treatment. In addition, the adaptive
plan was generated based on a positron emission tomogra-
phy/CT scan obtained after 5 to 6 weeks of treatment. This
may not have maximized the amount of dose given to the
regressed tumor.
Strength and Limitations of Our Study
Our study is one of the largest series to date document-
ing lung tumor regression and positional changes in a ho-
mogenous group of patients with advanced NSCLC treated
with concurrent chemotherapy and RT with curative intent.
We have demonstrated that a considerable proportion of lung
cancer patients experience significant tumor regression and
migration during the course of treatment. To minimize vari-
ations in setup, all scans were fused to the planning CT, and
4D cone beam images (exhale phase) were used for contours
to maximize accuracy of the tumor volumes and position.
Interobserver variability was minimized by the use of a single
observer, and images were contoured in a blinded fashion to
avoid further bias. However, it is acknowledged that intraob-
server variation may still occur. Although it would certainly
have been helpful to perform repeat contouring of the same
case, this would be challenging to perform and is beyond the
scope of this article. Our method is vulnerable to intraob-
server variability and the results do reflect observer experi-
ence, windowing preference in contouring, and other in-
herent biases. SEs for each measurement for the contoured
patients would certainly have been helpful in strengthening
the conclusions.
Despite detail provided by 4D CBCT, image quality is
inferior to diagnostic scans. Although only the primary tumor
was contoured, it may be possible to infer that the affected
nodal volumes would behave in a similar fashion. A study by
Bosmans et al.20 studied time trends in nodal volumes and did
not find significant volume changes. However, measurements
were made only up to week 2, and patients were not treated
with concurrent chemotherapy as was the case in our study.
There was also a large interpatient variation among the cohort
of 12 patients. The differences in tumor behavior between the
primary mass and nodal masses have yet to be clarified.
Overall, our study has sought to definitively study lung
tumor regression and migration using a large homogenous
patient population and has accounted for setup and respira-
tory motion.
Clinical Implications
By investigating lung tumor regression and migration,
our study aimed to assess the potential feasibility of adaptive
RT in patients with NSCLC. Adapting RT might allow higher
doses to be delivered to tighter volumes of tissue. This may
be of benefit in situations where the doses to organs are
higher than desirable and in instances where the target shifts
outside the planning target volume.
Although we have determined that a considerable num-
ber of patients experience significant tumor volume reduction
mid-treatment, there are still unanswered questions as to the
safety and practicality of reducing target volumes mid-treat-
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ment. Studies have shown microscopic extension of disease
beyond gross tumor up to 1.2 cm.21 As tumors regress, they
may continue to leave a similar perimeter of microscopic
disease, and further research is necessary to evaluate whether
reducing target volumes mid-treatment results in marginal
failure as a result of this hypothetical concern.
However, several studies have shown the potential
benefit for adaptive RT to dose escalate or spare normal
tissue. Ramsey et al.15 and Woodford et al.11 both found
benefits to adaptive planning in their models.
CONCLUSION
rcCBCT image quality allows assessment of tumors
located more peripherally. Significant tumor regression was
detected in the majority of patients with locally advanced
NSCLC treated with concurrent chemotherapy. These data
support further investigation into the role of adaptive plan-
ning strategies in lung malignancy in this group of patients.
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